PTN News 1.13 Palatin Technologies (PTN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Palatin Technologies (PTN) 1.13 $PTN

Global Female Sexual Dysfunction therapeutics Pipeline Review 2014: Analysis of 6 Companies and 11 Drug Profiles
M2 - Tue Apr 15, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kb4tcq/female_sexual) has announced the addition of the "Female Sexual Dysfunction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Sexual Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Female Sexual Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Female Sexual Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Female Sexual Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Female Sexual Dysfunction - Companies Involved in Therapeutics Development - Palatin Technologies, Inc. - M et P Pharma AG - ANI Pharmaceuticals, Inc. - Fabre-Kramer Pharmaceuticals, Inc. - EndoCeutics, Inc. - S1 Biopharma, Inc. Drug Profiles - testosterone - prasterone - TGWOO-AA - bremelanotide - TBS-2 - (bupropion trazodone hydrochloride) - TBS-2 - PL-6983 - S1B-307 - S1B-3006 - Next Generation Melanocortin Receptor Specific Peptide For more information visit http://www.researchandmarkets.com/research/kb...ale_sexual

Stocks Review on Top Gainers -- Research on EPAM Systems, JAKKS Pacific, BofI Holding, and Palatin Technologies
PR Newswire - Mon Apr 14, 7:00AM CDT
The US markets saw a negative sentiment on Friday, April 11, 2014, with the NASDAQ Composite closing at 3,999.73, down 1.34%, the Dow Jones Industrial Average ending the session at 16,026.75, down 0.89%, and the S&P 500 edging 0.95% lower to finish the trading session at 1,815.69. The losses were broad based as all the 10 sectors ended the session in negative. A number of stocks saw large movements, including EPAM Systems Inc. (NYSE: EPAM), JAKKS Pacific Inc. (NASDAQ: JAKK), BofI Holding Inc. (NASDAQ: BOFI) and Palatin Technologies Inc. (NYSE: PTN). Free technical research on EPAM, JAKK, BOFI and PTN can be downloaded upon signing up at:

Palatin Technologies Inc. (PTN) Jumps: Stock Up 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 7:51AM CDT
Palatin Technologies Inc. was a big mover last session, as its shares rose over 8% on the day.

Palatin Technologies' option to license out Bremelanotide in Europe extended until 30 April 2014
M2 - Tue Apr 01, 6:32AM CDT
Biopharmaceutical company Palatin Technologies (NYSE MKT TN) said on Monday that it has received an extension until 30 April 2014 to an existing option agreement with a potential European partner for an exclusive license to the former's bremelanotide for female sexual dysfunction in selected European countries, including the EU.

Palatin Technologies Announces Option Extension for License to Bremelanotide in Europe
PR Newswire - Mon Mar 31, 3:15PM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for an exclusive license to bremelanotide for female sexual dysfunction indications in selected European countries, including the European Union.

Morning Briefing on Stocks hitting New Milestones -- Research on Finisar, Analog Devices, Palatin Technologies and Green Plains Renewable
PR Newswire - Fri Mar 21, 5:04PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite finished at 4,319.29, up 0.27%. The Dow Jones Industrial Average closed the session at 16,331.05, up 0.67% and the S&P 500 ended the day at 1,872.01, higher by 0.60%. The gains were broad based with nine out of 10 sectors ending the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Finisar Corp. (NASDAQ: FNSR), Analog Devices Inc. (NASDAQ: ADI), Palatin Technologies Inc. (AMEX: PTN) and Green Plains Renewable Energy Inc. (NASDAQ: GPRE). Free technical research on FNSR, ADI, PTN and GPRE can be downloaded upon signing up at:

Palatin Technologies (PTN) Worth Watching: Stock Soars 15.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:25AM CDT
Palatin was a big mover last session, with shares rising nearly 16% on the day.

Palatin Technologies To Present At The 26Th Annual ROTH Conference
PR Newswire - Thu Mar 06, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 26th Annual ROTH Conference on Tuesday, March 11, 2014, at 3:30 p.m. Pacific Time. The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA.

Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder
PR Newswire - Mon Feb 24, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD), both which are forms of female sexual dysfunction (FSD).1,2,3

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on February 18, 2014
PR Newswire - Tue Feb 18, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2013.

Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.

Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2014 Results
PR Newswire - Thu Feb 13, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2014 operating results on Tuesday, February 18, 2014 before the open of the U.S. financial markets.

Palatin Technologies to Present at the 16th Congress of the European Society for Sexual Medicine
PR Newswire - Thu Jan 30, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunctions will be presented at the 16th Congress of the European Society for Sexual Medicine in Istanbul, Turkey on Friday, January 31, 2014 at 3:25 PM local time.

Palatin Technologies awarded USD1.85m in tax credits
M2 - Fri Jan 24, 4:59AM CST
US-based biopharmaceutical company Palatin Technologies Inc (NYSE MKT TN) reported on Thursday the receipt of about USD1.85m of non-dilutive funding via the State of New Jersey's Technology Business Tax Certificate Transfer Programme (the programme).

Palatin Technologies, Inc. Receives $1.85 Million from Sale of New Jersey State Tax Credits
PR Newswire - Thu Jan 23, 8:15AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that it has received approximately $1.85 million of non-dilutive funding via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program).

Palatin Technologies to participate at Noble Financial Capital Markets' Tenth Annual Equity Conference
M2 - Mon Jan 20, 8:11AM CST
Biopharmaceutical company Palatin Technologies Inc (NYSE MKT TN) said on Friday that it will give a presentation at 'TEN', Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida.

Palatin Technologies to Present at "TEN", Noble Financial Capital Markets' Tenth Annual Equity Conference
PR Newswire - Thu Jan 16, 3:00PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), announced today that Dr. Carl Spana, President and Chief Executive Officer, will present at "TEN", Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 20, 2014 at 11:30 a.m. Eastern Time.

Palatin Technologies Responds to Unusual Market Activity
PR Newswire - Mon Jan 13, 3:30PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) (the "Company" announced today that in view of the unusual market activity in common stock of the Company on Monday, January 13, 2014, the NYSE MKT (the "Exchange" has contacted the Company in accordance with the Exchange's usual practice. The Company stated that its policy is not to comment on unusual market activity.

LifeSci Advisors Initiates Coverage of Palatin Technologies, INC.
Marketwire - Wed Jan 08, 8:00AM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Palatin Technologies, Inc. (NYSE MKT: PTN), whose lead clinical candidate bremelanotide is set to enter Phase III trials in 2014 for female sexual dysfunction (FSD). Bremelanotide is an on-demand melanocortin receptor agonist that acts in the central nervous system to positively impact sexual response. The treatment is being developed for the large FSD indication that includes up to 20% of women in the US, but for which there is no FDA-approved drug treatment.

Palatin Technologies To Participate In The 25th Annual Piper Jaffray Healthcare Conference
PR Newswire - Mon Dec 02, 3:00PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that Dr. Carl Spana, the Company's chief executive officer, will participate in a "Fireside Chat" at the 25th Annual Piper Jaffray Healthcare Conference at 4:00 p.m. ET on December 4, 2013. The conference will be held at the New York Palace hotel in New York City. A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com. The live audio broadcast will be available through December 10, 2013.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 76

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 40

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 42

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading

Top 5 Most Recently Viewed Articles

Forian Inc.'s Key Participation in ROTH MKM Annual Event

Updated Category News Views 92

Forian Inc. Engages at ROTH MKM Technology Event In a significant move within the technology sector, Forian Inc. (Nasdaq: FORA) is preparing for participation in the prestigious ROTH MKM 13th Annual Technology Event. The event promises an engaging platform for discussions surrounding technological advancements and investment opportunities. Who Will Represent Forian Inc.?...

Continue Reading
Davidson Kempner Capital Management Updates Direct Line Holdings

Updated Category News Views 202

Introduction to the Disclosure This article provides an overview of a significant disclosure regarding holdings in Direct Line Insurance Group PLC by Davidson Kempner Capital Management LP. As a major financial actor, Davidson Kempner plays a critical role in the financial ecosystem, particularly in how it approaches its investments and holdings. Key Information on...

Continue Reading
Uncovering Dropbox's Unique Marketing Strategies for Success

Updated Category News Views 360

Drew Houston’s Key Marketing Insights Dropbox (NASDAQ: DBX) has transformed from a simple file storage service into a multibillion-dollar enterprise, largely due to the strategic marketing insights shared by CEO Drew Houston. During a notable event at Stanford University, he discussed two crucial hacks that have led to a surge of paying customers. The core idea is...

Continue Reading
22nd Century's Transformation: Debt Erased, Growth Ahead

Updated Category News Views 229

22nd Century Group Transforms with Debt-Free Balance Sheet 22nd Century Group, Inc. (NASDAQ: XXII) has made significant strides in its financial stability by completely eliminating $3.9 million in senior secured debt. This remarkable feat not only lowers their ongoing cash needs but resets the financial landscape for the company, enabling them to redirect resources...

Continue Reading
Empowering QUBT Shareholders: Your Rights and Legal Options

Updated Category News Views 170

Understanding Your Rights as a Shareholder of Quantum Computing Inc. As a shareholder of Quantum Computing Inc. (NASDAQ: QUBT), it's essential to be aware of your rights regarding the ongoing legal issue facing the company. You may have heard of a recent class action lawsuit aimed at Quantum Computing, and it's vital to understand how this could impact you as an investor....

Continue Reading